Recent Progress in Gels for Neuropathic Pain

Pușcașu, Ciprian; Zanfirescu, Anca; Negreș, Simona

doi:10.3390/gels9050417

Cited by 4 publications

(1 citation statement)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the diversity of mechanisms implicated in the occurrence of DN, there is a great need for new therapeutic options with improved efficacy in treating this pathology. Currently, therapeutic strategies have limited success in reducing pain, as well as a high risk of adverse reactions [ 19 ]. Tricyclic antidepressants (amitriptyline), calcium channel blockers (gabapentin, pregabalin), and serotonin and norepinephrine reuptake inhibitors (duloxetine, venlafaxine) are recommended as first-line treatments according to the American Academy of Neurology (AAN) [ 20 ] and European Federation of Neurological Society (EFNS) [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

The Influence of Sildenafil–Metformin Combination on Hyperalgesia and Biochemical Markers in Diabetic Neuropathy in Mice

Pușcașu,

Ungurianu,

Șeremet

et al. 2023

Medicina

Self Cite

View full text Add to dashboard Cite

Background and objectives: Worldwide, approximately 500 million people suffer from diabetes and at least 50% of these people develop neuropathy. Currently, therapeutic strategies for reducing diabetic neuropathy (DN)-associated pain are limited and have several side effects. The purpose of the study was to evaluate the antihyperalgesic action of different sildenafil (phosphodiesterase-5 inhibitor) and metformin (antihyperglycemic agent) combinations in alloxan-induced DN. Methods: The study included 100 diabetic mice and 20 non-diabetic mice that were subjected to hot and cold stimulus tests. Furthermore, we determined the influence of this combination on TNF-α, IL-6 and nitrites levels in brain and liver tissues. Results: In both the hot-plate and tail withdrawal test, all sildenafil–metformin combinations administered in our study showed a significant increase in pain reaction latencies when compared to the diabetic control group. Furthermore, all combinations decreased blood glucose levels due to the hypoglycemic effect of metformin. Additionally, changes in nitrite levels and pro-inflammatory cytokines (TNF-α and IL-6) were observed after 14 days of treatment with different sildenafil–metformin combinations. Conclusions: The combination of these two substances increased the pain reaction latency of diabetic animals in a dose-dependent manner. Moreover, all sildenafil–metformin combinations significantly reduced the concentration of nitrites in the brain and liver, which are final products formed under the action of iNOS.

show abstract

Section: Introductionmentioning

confidence: 99%

The Influence of Sildenafil–Metformin Combination on Hyperalgesia and Biochemical Markers in Diabetic Neuropathy in Mice

Pușcașu,

Ungurianu,

Șeremet

et al. 2023

Medicina

Self Cite

View full text Add to dashboard Cite

show abstract

Harnessing the power of biological macromolecules in hydrogels for controlled drug release in the central nervous system: A review

Ghosh,

Sharma

et al. 2024

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Effect of esketamine combined with pregabalin on acute postsurgical pain in patients who underwent resection of spinal neoplasms: a randomized controlled trial

Zhou,

Sun,

et al. 2024

Pain

View full text Add to dashboard Cite

Moderate-to-severe acute postsurgical pain (APSP) can prolong the recovery and worsen the prognosis of patients who undergo spinal surgery. Esketamine and pregabalin may resolve APSP without causing hyperpathia or respiratory depression after surgery. However, there are other risks, such as dissociative symptoms. We designed a randomized controlled trial to investigate the effect of the combination of these 2 drugs on the incidence of APSP in patients who underwent resection of spinal neoplasms. Patients aged 18 to 65 years were randomized to receive esketamine (a bolus dose of 0.5 mg·kg−1 and an infusion dose of 0.12 mg·kg−1·h−1 for 48 hours after surgery) combined with oral pregabalin (75-150 mg/day, starting 2 hours before surgery and ending at 2 weeks after surgery) or an identical volume of normal saline and placebo capsules. The primary outcome was the proportion of patients with moderate-to-severe APSP (visual analog scale score ≥ 40) during the first 48 hours after surgery. Secondary outcomes included the incidence of drug-related adverse events. A total of 90 patients were randomized. The incidence of moderate-to-severe APSP in the combined group (27.3%) was lower than that in the control group (60.5%) during the first 48 hours after surgery (odds ratio = 0.25, 95% CI = 0.10-0.61; P = 0.002). The occurrence of mild dissociative symptoms was higher in the combined group than in the control group (18.2% vs 0%). In conclusion, esketamine combined with pregabalin could effectively alleviate APSP after spinal surgery, but an analgesic strategy might increase the risk of mild dissociative symptoms.

show abstract

Recent Progress in Gels for Neuropathic Pain

Cited by 4 publications

References 108 publications

The Influence of Sildenafil–Metformin Combination on Hyperalgesia and Biochemical Markers in Diabetic Neuropathy in Mice

The Influence of Sildenafil–Metformin Combination on Hyperalgesia and Biochemical Markers in Diabetic Neuropathy in Mice

Harnessing the power of biological macromolecules in hydrogels for controlled drug release in the central nervous system: A review

Effect of esketamine combined with pregabalin on acute postsurgical pain in patients who underwent resection of spinal neoplasms: a randomized controlled trial

Contact Info

Product

Resources

About